Redhill Biopharma
RDHL
6 hedge funds and large institutions have $11.9M invested in Redhill Biopharma in 2014 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
14% less funds holding
Funds holding: 7 → 6 (-1)
25% less capital invested
Capital invested by funds: $15.9M → $11.9M (-$3.92M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$14.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $7.98M | – | – | – |
|
|
BC
2
Broadfin Capital
New York
| $3.47M | – | – | – |
|
3
Goldman Sachs
New York
| $382K | – | – | – |
|
|
MMG
4
Monetary Management Group
St Louis,
Missouri
| $58K | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $40K | – | – | – |
|
6
Bank of America
Charlotte,
North Carolina
| $13K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $5K | -$14.4K | -1 | Closed |
|
RDHL Hedge Fund Activity: Q3 2014 in Review
6 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Redhill Biopharma (RDHL) for Q3 2014, worth a combined $11.9M — down 25% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RDHL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $14.4K sold.
- 6 institutional investors held Redhill Biopharma (RDHL) as of Q3 2014, down from 7 in Q2 2014.
- Funds reported $11.9M of Redhill Biopharma stock for Q3 2014, down 25% quarter-over-quarter.
- 0 funds opened new Redhill Biopharma positions in Q3 2014 and 1 closed out, a net change of -1 holder.
- The largest Redhill Biopharma seller in Q3 2014 was Tower Research Capital (TRC), an estimated $14.4K sold.
Based on aggregated 13F filings for Q3 2014.